Skip to content
Blood Test Tracker

Free Kappa/Lambda Light Chain Ratio

Compares kappa with lambda free light chains. A lopsided ratio can be a clue to a plasma cell condition, but kidney disease also shifts it.

AI-verified against cited sources. Awaiting expert reviewAlso called K/L ratio, FLC ratioLOINC 48378-4

Check your result

Sex (optional)

Type your result to see where it falls.

Nothing you type here leaves your browser.

What it is

The kappa/lambda ratio is the free kappa result divided by the free lambda result. In healthy people the two types are made in a steady balance, so the ratio stays inside a fairly narrow range. When one clone of plasma cells makes too much of one type, the ratio tips. Your lab calculates it from the two free light chain results, and it is usually printed right below them.

Why it matters

The ratio is the key number on a free light chain test. It is more telling than either chain alone, because reduced kidney function raises both chains together and moves the ratio only a little. Clinicians use it with protein electrophoresis and immunofixation to look into monoclonal gammopathy (MGUS), multiple myeloma and light chain (AL) amyloidosis, and to follow people who have them. A ratio outside the range is not a diagnosis, and it is common in people with reduced kidney function. In a large Icelandic study of people with an eGFR below 60, 9% had a ratio outside the standard range, but fewer than 1% had light chain MGUS. For myeloma, the International Myeloma Working Group counts an involved-to-uninvolved ratio of 100 or more, with the involved chain at 100 mg/L or more, as a myeloma-defining finding.

If it’s low

A ratio below your lab's range means lambda is higher than expected compared with kappa. This is less common than a high ratio. In some people it comes from a lambda-producing clone of plasma cells, so your clinician may order more tests. A value near the edge of the range can also reflect differences between methods, and your clinician may repeat it.

Common causes

  • A value near the edge of the range, which a repeat test or a different method can settle
  • Differences between lab methods
  • Lambda light chain MGUS
  • Multiple myeloma, AL amyloidosis or related conditions

What can help

  • Ask whether the result should be repeated or checked alongside protein electrophoresis and immunofixation
  • If you are followed over time, use the same lab and method each time

If it’s high

A ratio above your lab's range means kappa is higher than expected compared with lambda. The most common explanations are reduced kidney function, which pushes the ratio up a little, older age, and natural variation between groups of people. Your clinician will usually look at your kidney function and may order protein electrophoresis and immunofixation. In some people a high ratio comes from a kappa-producing clone of plasma cells. Light chain MGUS means an unusual ratio and a raised kappa chain without organ damage, and it is usually followed over time.

Common causes

  • Reduced kidney function, which raises the ratio a little
  • Older age
  • Long-term inflammation or high levels of normal antibodies (polyclonal hypergammaglobulinemia)
  • Natural variation that standard ranges do not capture, which studies have described in people of African ancestry
  • Differences between lab methods
  • Light chain MGUS or another monoclonal gammopathy
  • Multiple myeloma, AL amyloidosis or related conditions

What can help

  • Ask your clinician how your kidney function (eGFR) fits with this result, and whether a kidney-based range applies
  • Ask whether protein electrophoresis and immunofixation were done with it
  • If you are followed over time, use the same lab and method each time

Usual ranges

What labs print as the reference range, by who was tested. Ranges differ a little between labs, so the range on your own report is the one your result is judged against.

For adults: 0.26–1.65 ratio. Source: Clinical Chemistry, ARUP Laboratories, University of Iowa Hospitals & Clinics Pathology Handbook, Mayo Clinic Laboratories (Extended Catalog), Biochemia Medica, Blood.

What can affect your result

  • Kidney function: the ratio rises a little as eGFR falls (median 1.13 at eGFR 45–59 and 1.31 to 1.33 below 30 in the iStopMM cohort)
  • Age: in the same cohort the median ratio rose from 1.05 under age 50 to 1.23 at age 80 and over
  • Ancestry: a 2025 study of about 9,000 people proposed a ratio range of 0.686–2.10 for people of African ancestry with normal kidney function
  • Inflammation, autoimmune disease and high levels of normal antibodies can raise both chains and move the ratio
  • Lab method: Freelite and N Latex FLC give different ratios and use different ranges
  • Kidney function: reduced eGFR shifts the ratio upward a little and raises both chains, so a ratio outside the standard range is more common in kidney disease. A separate kidney interval exists.
  • Methods differ: Freelite and N Latex FLC give different ratios and use different ranges, and some labs print their own intervals. Results from different methods are not interchangeable.
  • The ratio divides one chain by the other, so an error in either chain changes it. Labs may repeat or dilute unusual samples.
  • Antigen excess: very high amounts of one light chain can read falsely low on some assays, which can hide a lopsided ratio. ARUP notes it cannot be fully excluded.
  • Chronic inflammation, autoimmune disease or high levels of normal antibodies can raise both chains and move the ratio.

Free light chains leave the blood within hours when the kidneys work normally (reported half-lives are roughly 2 to 6 hours), so levels can respond quickly to change. Clearance is slower in kidney disease, up to about 30 hours in advanced chronic kidney disease.

When to talk to a clinician

If your kappa/lambda ratio is outside your lab's range, mention it to your clinician, who can read it alongside your kidney function and other tests. Talk with your care team promptly if you have been told you have a plasma cell condition and your numbers are rising. If you already have a plasma cell condition, contact your care team promptly about new bone pain, new weakness or tiredness, signs of high calcium (such as thirst, constipation or confusion), or a drop in kidney function. These match the organ-damage features (calcium, kidney, anemia, bone) used to define myeloma.

Questions you could ask

  • Which method does my lab use, and should I use the same lab for future tests?
  • Does a kidney-based range apply to me?
  • Could my kidney function or age explain this ratio?
  • Were protein electrophoresis and immunofixation done, and what did they show?
  • Should we repeat this test, and when?
  • Should we repeat this test or check it with a different method?

Questions people ask

My kappa and lambda are both high but my ratio is in range. Is that a concern?

This pattern is common when the kidneys clear light chains more slowly. The ratio helps because reduced kidney function raises both chains and moves the ratio only slightly. Long-term inflammation can do the same. Your clinician will read it together with your eGFR.

Why is my lab's range different from 0.26–1.65?

Different tests use different reagents and different ranges. Siemens N Latex FLC lists 0.31–1.56, and Mayo Clinic Laboratories prints 0.57–2.45. If your kidney function is reduced, labs sometimes use 0.37–3.10. The range printed on your own report is the one to use.

Does a ratio outside the range mean I have myeloma?

No. Many people with a ratio outside the range have reduced kidney function, inflammation or normal variation. In a large Icelandic study of people with reduced kidney function, 9% had a ratio outside the standard range, but fewer than 1% had light chain MGUS. A diagnosis of myeloma needs several tests, including tests of the bone marrow, and a specialist's review.

Show the science and sources

For clinicians and researchers

The ratio is calculated as free kappa divided by free lambda; Mayo Clinic Laboratories lists it as a calculation. The standard Freelite interval of 0.26–1.65 came from a diagnostic interval in adults aged 21 to 90 with normal kidney function (Katzmann 2002), and the ratio showed no age trend in that study. The kidney interval of 0.37–3.10 came from a cohort of 688 people with CKD (Hutchison 2008; median eGFR 29 according to the iStopMM paper) and was later validated in a cohort of people with myeloma on dialysis, but not in earlier CKD stages. In iStopMM (about 6,500 people with eGFR below 60, no monoclonality, Freelite), 9% had a ratio above the standard interval, 0.1% below it and 0.7% fell outside the kidney interval. New central 99% ratio intervals were 0.46–2.62 (eGFR 45–59), 0.48–3.38 (30–44) and 0.54–3.30 (below 30), with median ratios of 1.13 (eGFR 45–59), 1.21 (30–44) and 1.31 to 1.33 (below 30); the authors argue current intervals misclassify people with CKD, and that the prevalence of light chain MGUS in CKD was about 0.5%. Manufacturer intervals differ by method (Freelite 0.26–1.65, N Latex FLC 0.31–1.56), and Mayo Clinic Laboratories prints 0.57–2.45. A comparison of 93 samples found the two assays were not interchangeable: Freelite gave higher ratios, and 61 samples were outside the range on Freelite against 38 on N Latex. The IMWG guidelines were built on Freelite values. A comparison paper also notes the ratio can fall falsely outside the range in polyclonal hypergammaglobulinemia and falsely inside the range in some samples with a lambda monoclonal protein. A 2025 Blood study (PROMISE and Mass General Brigham Biobank, 9,028 people negative for heavy chain monoclonal gammopathy) found light chain MGUS in 14.8% of Black and 4% of White US participants using standard ranges, 99% of it kappa-restricted, and proposed 0.686–2.10 for people of African ancestry with normal kidney function, which cut the apparent light chain MGUS by 91%. In the 2014 IMWG criteria, an involved-to-uninvolved FLC ratio of 100 or more with an involved FLC of 100 mg/L or more is a myeloma-defining event. Light chain MGUS is a ratio outside the reference interval with a raised involved chain, no heavy chain on electrophoresis or immunofixation, and no organ damage attributed to the plasma cell disorder. The IMWG (2009) supports serum FLC with electrophoresis and immunofixation for screening and serial FLC for oligosecretory disease. Intervals must not be mixed across assays, and ratios from different methods should not be compared.

LOINC 48378-4 (primary), 104546-7, 80517-6. Specimen: calculated.

Sources

  1. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains, Clinical Chemistry (2002)
  2. Kappa/Lambda Quantitative Free Light Chains with Ratio, Serum (test 0055167), ARUP Laboratories
  3. Kappa-Lambda Quant Free Light Chain Ratio, Blood, University of Iowa Hospitals & Clinics Pathology Handbook
  4. Immunoglobulin Free Light Chains, Serum (test FLCS), Mayo Clinic Laboratories (Extended Catalog)
  5. Comparison of Freelite and N-Latex serum free light chain assays: a critical review, Biochemia Medica (2021)
  6. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease, Clinical Journal of the American Society of Nephrology (2008)
  7. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study, Blood Cancer Journal (2022)
  8. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders, Leukemia (2009)
  9. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, The Lancet Oncology (2014)
  10. Serum free light chains in a racially diverse population including African Americans and populations from South Africa, Blood (2025)
  11. Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy, Journal of Clinical Medicine (2026)
  12. Elevated serum polyclonal immunoglobulin free light chains in patients with severe asthma, Frontiers in Pharmacology (2023)
  13. Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update, Diagnostics (Basel) (2024)

AI-verified against cited sources. Awaiting expert review. Last reviewed 2026-10-03. How we build and check these pages.

Calculators

Related markers